canadian association of gastroenterology clinical practice guidelines: the use of tumour necrosis factor-alpha antagonist therapy in crohn’s disease
Clicks: 236
ID: 229119
2009
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
236 views
47 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #37 of 250 articles by views in indian journal of pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 250 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Guidelines regarding the use of infliximab in Crohn’s disease were previously published by the Canadian Association of Gastroenterology in 2004. However, recent clinical findings and drug developments warrant a review and update of these guidelines.
| Reference Key |
sadowski2009canadiancanadian
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Daniel C Sadowski;Charles N Bernstein;Alain Bitton;Ken Croitoru;Richard N Fedorak;Anne Griffiths;the CAG Crohn’s Consensus Group |
| Journal | indian journal of pharmacology |
| Year | 2009 |
| DOI |
10.1155/2009/201430
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.